AbbVie (ABBV) shines post-Allergan acquisition, boasting a revamped portfolio and promising long-term growth. The stock hits all-time highs with a 100% Barchart “Buy” rating and positive analyst sentiment. Valued at $394 billion, AbbVie now dominates the pharma industry, less reliant on Humira due to new drug additions.

Imbruvica, Skyrizi, and Rinvoq bolster AbbVie’s cancer and immunology offerings, setting the stage for substantial growth. AbbVie leads in various therapeutic areas, from oncology to women’s health. Technical indicators show strong momentum, with a Trend Seeker “Buy” signal since July, resulting in an 18.74% gain.

AbbVie’s stellar performance continues with an all-time high of $232.35 and a Weighted Alpha of +28.72. The stock maintains a solid 100% “Buy” opinion, climbing 17.25% in the past year. With multiple new highs and a Trend Seeker “Buy” intact, AbbVie remains a top contender in the market.

AbbVie boasts a market cap of $394 billion, a 20.83x P/E ratio, and a 2.83% dividend yield. Revenue and earnings are projected to rise significantly this year and next. Wall Street analysts and individual investors alike are bullish on ABBV, with price targets ranging from $190-$270 and numerous “Buy” ratings.

Positive sentiments from financial advisory sites and individual investors support AbbVie’s upward trajectory. Strong revenue and earnings projections, as well as favorable price targets, indicate further growth potential. With broad backing and a positive outlook, AbbVie appears poised for continued success.

Read more at Yahoo Finance: AbbVie Stock Is Just What the Doctor Ordered